- WHATS NEW?
- Reconstituted HDL lowers plaque lipids, macrophage size and measures of inflammation
- Ethnic differences in antipsychotic effects on HDL
- Increasing prevalence of low HDL cholesterol/elevated triglycerides highlights need for more comprehensive lipid control
- CETP genotypes, HDL cholesterol and coronary risk
- High-density lipoprotein and inflammation - new insights
Results from first poll now available
First in vivo data on reconstituted HDL
Click here for the full article
Dalcetrapib, a novel CETP inhibitor, does not increase aldosterone production
Click here for the full article
High-density lipoprotein cholesterol
and cardiovascular disease risk
The HDL Forum aims to provide healthcare professionals with peer-reviewed online analysis of the latest developments in scientific research and clinical management of high-density lipoprotein (HDL) cholesterol - 'good cholesterol'.
HDL is one of the hottest topics in lipid research and cardiovascular disease prevention today. Epidemiological and observational studies have established HDL cholesterol as an important independent cardiovascular risk factor. Recent research also shows that HDL plays a key role in the prevention, or even reversal, of atherosclerosis.
The Editorial Board of HDL Forum is comprised of individuals with an international reputation for leadership in HDL research, atherosclerosis and cardiovascular disease prevention. HDL Forum provides expert commentary on key developments in all of these fields, reporting regularly
from the major international meetings to ensure up to the minute coverage.
- Latest reports on HDL Research in HDL Biology
- Upcoming meetings and reports in News
- Expert commentaries in Forum
- Correspondence welcomed ? click here for submission details
- Register now to receive your discount on 'High Density Cholesterol: The New Target'
Members of the Editorial Board of HDL Forum are internationally known for innovative leadership in HDL research, atherosclerosis and cardiovascular disease prevention.
Professor Kerry-Anne Rye, Lead Editor of HDL Forum: Professor in the Faculty of Medicine, University of Sydney, and Associate Director and Head of the Lipid Research Group, Heart Research Institute, Sydney, Australia.
Heart Research Insitute
Professor Philip Barter: Professor of Medicine, University of Sydney and Director of the Heart Research Institute, Sydney, Australia.
Heart Research Institute
Dr H Bryan Brewer: Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington DC, USA.
MedStar Research Institute
Professor Alan Chait: Edwin L. Bierman Professor of Medicine, Head, Division of Metabolism, Endocrinology and Nutrition and Director of Clinical Nutrition Research Unit, University of Washington, Seattle, USA.
University of Washington, CNRU
Professor M John Chapman: Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute of Health and Medical Research (INSERM), Piti?-Salp?tri?re Hospital, Paris, France.
Institute of Health and Medical Research
Professor John JP Kastelein: Professor of Medicine and Chairman of the Department of Vascular Medicine, Academic Medical Center of the University of Amsterdam, Strategic Chair of Genetics of Cardiovascular Disease and Director of the Atherosclerosis Research Group.
AMC
Dr Anthony Wierzbicki: Director of the Lipid Unit, Guys? and St. Thomas? NHS Foundation Trust, London UK.
Guys? and St. Thomas? NHS Foundation Trust
Corporate sponsor
